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Abstract
Precise crosstalk between the nervous and immune systems is important for neuroprotection and axon plasticity
after injury. Recently, we demonstrated that IL-1β acts as a potent inducer of neurite outgrowth from organotypic
brain slices in vitro, suggesting a potential function of IL-1β in axonal plasticity. Here, we have investigated the
effects of IL-1β on axon plasticity during glial scar formation and on functional recovery in a mouse model of spinal
cord compression injury (SCI). We used an IL-1β deficiency model (IL-1βKO mice) and administered recombinant
IL-1β. In contrast to our hypothesis, the histological analysis revealed a significantly increased lesion width and a
reduced number of corticospinal tract fibers caudal to the lesion center after local application of recombinant IL-1β.
Consistently, the treatment significantly worsened the neurological outcome after SCI in mice compared with PBS
controls. In contrast, the absence of IL-1β in IL-1βKO mice significantly improved recovery from SCI compared with
wildtype mice. Histological analysis revealed a smaller lesion size, reduced lesion width and greatly decreased
astrogliosis in the white matter, while the number of corticospinal tract fibers increased significantly 5 mm caudal
to the lesion in IL-1βKO mice relative to controls. Our study for the first time characterizes the detrimental effects of
IL-1β not only on lesion development (in terms of size and glia activation), but also on the plasticity of central
nervous system axons after injury.
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Introduction
IL-1β is a 17 kDa protein and is one of the most exten-
sively studied proinflammatory cytokines. IL-1β is al-
most undetectable in the undamaged central nervous
system (CNS), but its expression increases several fold
after injury (including neurotoxic stimuli, ischemia and
trauma) [1]. Microglia are the principal cells expressing
IL-1β, but many other resident cells (including astro-
cytes and neurons) or invading cells are also able to pro-
duce the cytokine [2]. IL-1β mainly acts by activating
the immune response, fostering the production of in-
flammatory mediators and other cytokines. Interestingly,
when applied on healthy neurons, IL-1β does not cause
damage or death; however, it induces a number of
cellular reactions such as changes in intracellular cal-
cium concentrations and ionic conductances [3,4]. In an
organotypic model we recently demonstrated that IL-1β
is a potent inducer of neurite outgrowth from brain
slices [5], suggesting a potential function of IL-1β in
axonal plasticity. This is in contrast to its well-studied
contribution to both acute neuronal loss and chronic
neurodegeneration [1]. Despite the intensive research on
IL-1β in recent decades, its role in the CNS remains far
from fully understood. The in vitro effects of IL-1β are
very heterogeneous. IL-1β supports survival of dorsal root
ganglion neurons [6] and pyramidal neurons in vitro [7],
but it also induces depolarization, increases the spike fre-
quency and enhances vulnerability of hippocampal neu-
rons induced by N-methyl-D-aspartate receptor-mediated
increase of intracellular calcium [4]. IL-1β also has strong
effects on astrocytes, promoting activation, proliferation
and production of neurotoxic mediators, as well as survival
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promoting factors [8]. Studies from our group showed ei-
ther no effects of IL-1β on neurotrophin-induced out-
growth from dorsal root ganglion neurons [9] and spinal
cord explants or a beneficial effect on axonal growth from
brain slices in vitro [5]. The in vivo role of IL-1β is also not
clear. Intracerebroventricular administration of IL-1β dur-
ing ischemic damage after permanent middle cerebral ar-
tery occlusion results in a highly enhanced infarct volume
(~92%) [10], similar to the effect of systemic [11] or local
[12] administration of the cytokine in mice with middle
cerebral artery occlusion. Moreover, IL-1β leads to exacer-
bated cell death and neurodegeneration in other experi-
mental models of CNS trauma [13,14]. In contrast, there is
evidence that IL-1β is necessary for proper remyelination
of the CNS following death of mature oligodendrocytes
since IL-1β−/− nerve fibers are unable to remyelinate prop-
erly after cuprizone-induced demyelination [15]. Finally,
IL-1β contributes to sensory nerve regeneration in vivo fol-
lowing sciatic nerve injury [16,17].
In this study, we have investigated the effects of
increased local levels of IL-1β compared with IL-1β ab-
sence (in IL-1βKO mice) after compression of the spinal
cord [18]. In contrast to our in vitro-based hypothesis,
but in line with the results on IL-1βKO mice reported in
a recently published study from the Shioda laboratory
[19], we here demonstrate for the first time detrimental
effects of IL-1β on lesion development, in terms of le-
sion size and glial activation, and on the plasticity of
CNS axons in vivo after injury.
Materials and methods
Spinal cord compression injury
All experiments with C57BL/6 wildtype (WT) mice and
homozygous mice deficient in IL-1β [20] (IL-1βKO)
(females, 8 to 12 weeks old) were performed in accord-
ance with the German guidelines on the use of laboratory
animals. Spinal cord injury, corticospinal tract (CST)
tracing and subsequent analysis were carried out following
a standardized protocol [18,21]. Briefly, C57BL/6 mice
and IL-1β-deficient mice underwent a dorsal laminectomy
at thoracic level T8, and the compression of the spinal
cord was induced with a modified SPI Correx Tension/
Compression Gage (Penn Tool, Maplewood, NJ, USA) at
10 cN for 3 seconds. For recombinant IL-1β (rIL-1β) and
PBS application, a piece of Gelfoam (Pharmacia & Upjohn,
Erlangen, Germany) soaked in 5 μl solution with PBS
alone or with 1 or 20 μg rIL-1β was placed directly on top
of the injured spinal cord and in contact with the perfo-
rated dura before suturing the muscles. Important to note
in these experiments is that when recombinant cytokine
was applied, a Gelfoam patch was in direct contact with
the injured spinal cord, and this led to a lower score in
control mice compared with the WT mice in the knock-
out experiments. The rIL-1β in vivo dosage was based on
in vitro results coming from our group [5] demonstrating
that rIL-1β increases axonal outgrowth when applied in a
high therapeutic dosage in a well-established organotypic
slice culture model [22-25]. The effective dosage in that
study (500 ng rIL-1β in 500 μl medium) was substantially
higher than the concentrations found in vivo after spinal
cord injury (300 pg/ml in spinal cord (1 cm) homogenate
6 hours after injury). In the first experiment we therefore
applied a high therapeutic dosage of 20 μg rIL-1β in Gel-
foam, also taking into account that the dispersion of the
cytokine is higher in vivo than in vitro, that the time of ob-
servation is longer (2 days for in vitro experiments and
14 days for in vivo experiments) and that the lesion vol-
ume in the spinal cord is much bigger than a 350 μm thick
slice of the enthorinal cortex. Furthermore, to distinguish
between local and systemic effects on functional recovery,
a 100 μl solution of PBS alone or with 1 μg rIL-1β was
also applied systemically by intraperitoneal injection im-
mediately after injury.
Behavioral analysis
The spinal cord compression injury (SCI) mice were
tested over 14 days for functional recovery with the Basso
Mouse Scale (BMS) [26], which is a locomotor rating scale
ranging from 0 to 9 (0 = complete hind limb paralysis; 9 =
normal locomotion). In BMS testing, mice are scored
according to the mobility of the hind limbs for a period of
4 minutes in an open field by two investigators carefully
blinded to experimental groups. Furthermore, since sub-
scores for each parameter of the BMS can be used to
measure individual locomotor features [26] and since cor-
rect foot placing correlates with proper CST function
[27,28], stepping performance and correct paw positioning
were evaluated as previously described [18]. The analysis
of the stepping emphasized whether plantar stepping was
present in <50% or in >50% of the steps (scores 0 and 1,
respectively). For the scoring of paw positioning, we
assessed whether the paws were rotated at both initial
contact and lift-off (score 0), parallel at initial contact but
rotated at lift-off (score 1), or parallel at both initial con-
tact and lift-off (score 2). For both stepping performance
and paw positioning, the score for each animal was then
represented as a percentage, taking as 100% a score of, re-
spectively, 1 and 2. For the BMS, stepping performance
and paw positioning analysis we used the mean of the left
and right hindlimb scores for each animal. Data shown
represent mean values for all the animals of each experi-
mental group ± standard error of the mean and were ana-
lyzed using a two-way analysis of variance as described
previously [26].
Corticospinal tract tracing and analysis
For biotinylated dextran amine (BDA, 10%; Invitrogen,
Darmstadt, Germany) tracing, a small hole was drilled
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into the skull directly after SCI (after suturing the back
muscles) and a Hamilton syringe was inserted into the
motor cortex to apply 2 μl of 10% solution of the antero-
grade tracer. At the end of the observation period, CST
fibers were visualized by diaminobenzidine staining on
paraformaldehyde-fixed longitudinal cryosections (20 μm)
of the spinal cord. BDA-labeled nerve fibers of the corti-
cospinal tract were quantified at defined distances caudal
to the lesion center in the complete microscopic field
along the dorso-ventral axis at a total magnification of ×
400. Counted fibers are shown as a percentage of the total
number of labeled fibers within a standardized 20 μm
wide area of the dorso-ventral diameter of the CST at level
C4. Fibers were counted on five to seven adjacent sections
with a clearly recognizable lesion and CST end (presenting
retraction bulbs), and only the axons fulfilling the criteria
outlined by Steward and colleagues [29] were included in
the analysis. Data represent mean values ± standard error
of the mean and were analyzed using the Mann–Whitney
U test.
Evaluation of lesion size, lesion width and degree of
gliosis
Longitudinal spinal cord cryosections, 20 μm thick
(obtained from transcardially perfused animals at the
end of behavioral analysis period), were preincubated
in PBS with 10% normal goat serum containing 0.5%
Triton X-100 for 60 minutes at room temperature.
Incubation with primary antibodies was carried out
overnight at 4°C. Secondary antibodies were applied for
1 hour at room temperature. For measurement of the
lesion size and gliosis, three to six sections per animal,
the central part of the spinal cord included, were analyzed.
The lesion size and lesion width were evaluated by stain-
ing against ionized calcium binding adaptor molecule 1
(Iba1) using rabbit polyclonal antibodies (Wako Chemi-
cals, Neuss, Germany). Alexa Fluor 488 goat anti-rabbit
antibodies (Invitrogen) were applied as secondary anti-
body. The Iba1-positive area was quantified using image
analysis software (ImageJ open source software; Na-
tional Institutes of Health, Bethesda, MD, USA) and
averaged for each animal after the analysis of three to
six sections. The lesion size was evaluated on sagittal
sections and represents the mean area in the center of
the spinal cord (corresponding to the lesion center, in-
cluding the CST end), while the lesion width represents
the total number of sagittal sections presenting the le-
sion, multiplied by the thickness of each section. Iba1
intensity was calculated for the same area and was
found not to differ significantly between the experimen-
tal groups (data not shown). While the use of an Iba1-
positive area to measure the lesion size is not a classical
Figure 1 Dose-dependent mortality after spinal cord
compression injury. The mortality rate in mice with local
administration of recombinant IL-1β (rIL-1β) in Gelfoam directly after
spinal cord compression injury (SCI) was 100% in mice treated with
20 μg rIL-1β, and was significantly higher compared with mice
treated with 1 μg rIL-1β or only with PBS. P <0.0001 using the
log-rank test.
Figure 2 Application of recombinant IL-1β impairs neurological
outcome after spinal cord compression injury. (A) Locomotion
analysis using the Basso Mouse Scale (BMS) showed significant
worsening of neurological outcome after spinal cord compression
injury (SCI) and local administration of recombinant IL-1β (rIL-1β) in
Gelfoam directly after SCI. The rIL-1β-treated mice scored more than
1 point of the BMS less than control mice (scoring respectively 4.5
and 6), most probably reflecting lack of coordination and consistent
plantar stepping in the treated mice. (B) The paw positioning
subscore differed significantly between the two groups, while the
stepping subscore did not. *P <0.05, two-way analysis of variance.
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procedure, in this study we could not use traditional
glial fibrillary acidic protein (GFAP) immunoreactivity
measures for this goal (as often found in the literature
and as performed in previous work from our laboratory
[18]); this was due to the reduced GFAP immunoreac-
tivity in the IL-1βKO mice, which did not allow for
comprehensive analysis. Iba1 immunoreactivity in the
lesion, however, correlated perfectly well with the lesion
size found using bright-field microscopy, with the added
advantage that Iba1 immunoreactivity was much easier
to distinguish from the background. Astrogliosis was
evaluated using staining against GFAP with mouse mAb
(Sigma-Aldrich, St Louis, MO, USA). Alexa Fluor 568
goat anti-mouse (Invitrogen) was used as secondary
antibody. Quantification of GFAP expression was per-
formed as previously described [18,30] by means of in-
tensity analysis using ImageJ software within an area
100 μm wide along the dorso-ventral axis of the spinal
cord, extending from 600 μm cranial to 600 μm caudal
to the lesion center. Additionally, the total intensity of
GFAP staining in the white matter in the same area was
calculated for each animal in the rostro-caudal axis.
Data represent the mean ± standard error of the mean
and were analyzed using the Mann–Whitney-U test.
Results
In a first experimental approach we applied a high dos-
age of rIL-1β to mice that underwent spinal cord injury.
To our knowledge this is the first study to investigate
the in vivo effect of rIL-1β on axonal plasticity in the
CNS, so the choice of the rIL-1β in vivo dosage was based
on in vitro results from our group. Perilesional administra-
tion of 20 μg rIL-1β in Gelfoam immediately after SCI
resulted in 100% mortality, with all mice (n = 7) dying
within the first 4 days after the operation (Figure 1). We
refrained from repeating the experiment to perform nec-
ropsies to diagnose the cause of death for obvious ethical
reasons. Based on these results, we used a drastically
reduced amount of cytokine (1 μg in 5 μl PBS), which sub-
stantially reduced the mortality (only one out of eight
operated mice died 3 days after injury). The application of
1 μg rIL-1β significantly impaired functional performance
compared with mice treated with PBS alone (Figure 2A).
At the end of the investigation period (14 days after in-
jury) the two experimental groups varied by more than
one point on the BMS (from about 4.5 for rIL-1β-treated
mice to 6 for PBS-treated mice), mainly reflecting a sub-
stantial difference in coordination and consistency of plan-
tar stepping during walking. To rule out the possibility
Figure 3 Systemic application of recombinant IL-1β impairs
neurological outcome after spinal cord compression injury.
Locomotion analysis using the Basso Mouse Scale (BMS) showed a
significant early worsening of neurological outcome after spinal cord
compression injury (SCI) and systemic administration of recombinant
IL-1β (rIL-1β) compared with control mice. At days 1 and 2 after SCI,
the rIL-1β-treated mice scored more than 2 points of the BMS lower
than the control mice, but the significant difference was
progressively lost and they scored in the same range of values as
control mice at day 7 after lesion. *P <0.05, two-way analysis of
variance.
Figure 4 Absence of IL-1β in IL-1βKO mice promotes functional
outcome after spinal cord injury. (A) Locomotion analysis using
the Basso Mouse Scale (BMS) showed a significant increase of
neurological outcome after spinal cord compression injury (SCI) in
IL-1βKO mice, as evidenced by a difference of1 point of the BMS
between treatment groups (6.8 for wildtype (WT) mice and 7.8 for
IL-1βKO mice). (B) The paw positioning subscore was significantly
different between the two groups. Conversely, the stepping
subscore was almost identical. *P <0.05, two-way analysis of
variance.
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that the effect of rIL-1β-mediated worsened neurological
outcome after SCI was due to a systemic effect of the
cytokine, we applied 1 μg IL-1β systemically (intraperito-
neal injection) after lesion (Figure 3). Under these condi-
tions the treated mice showed a significant worsening of
neurological outcome from day 2 to day 5 of the observa-
tion period, scoring more than 2 points of the BMS less
than control mice in the first 2 days. They progressively
improved at a higher rate if compared with mice treated
only with PBS, and by day 7 of the scoring the significant
difference between the two groups was lost.
Conversely, the absence of IL-1β in IL-1βKO mice
significantly promoted functional recovery after SCI
compared with WT mice (Figure 4A), as indicated by a
difference of 1 point of the BMS between experimental
groups (from about 6.8 for the WT mice to about 7.8 for
IL-1βKO mice). Analysis of the stepping subscore of the
BMS showed a negative trend after administration of
Figure 5 Administration of recombinant IL-1β or absence of IL-1β alters numbers of corticospinal tract fibers. (A), (B) Representative
micrographs of the area of the spinal cord between the corticospinal tract (CST) end and 5 mm caudal to the lesion center (LC). Higher
magnification panels highlight the area between the end of the CST and the LC and one selected area (recombinant IL-1β (rIL-1β)) to four
selected areas (IL-1βKO) caudal to the LC, where diaminobenzidine-positive fibers could be detected. Arrows indicate CST fibers caudal to the LC.
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rIL-1β that did not reach significance, while in the paw
positioning subscore a statistically significant difference
was found (Figure 2B). On the contrary, IL-1β deficiency
led to an almost identical stepping score but significantly
improved the paw positioning score (Figure 4B), indicat-
ing that this parameter (degree of rotation of the hind
paws) is of particular relevance to the difference in the
functional recovery not only between PBS and rIL-1β-
treated mice, but also between knockout and WT mice.
In the next step, we analyzed the number of BDA-traced
CST fibers as a marker for axonal plasticity induced by
absence or increased levels of IL-1β at defined distances
from the lesion center (Figures 5 and 6). Treatment of
the injured mice with rIL-1β significantly reduced the
number of labeled axons 5 mm distal to the lesion cen-
ter compared with PBS-treated mice (Figure 5, upper
panels and Figure 6A). In contrast, IL-1β absence in IL-
1βKO mice led to a significant increase of BDA-positive
fibers in the area 5 mm distal to the lesion and to the
development of complex branches (Figure 5, lower
panels and Figure 6B). Quantification of BDA-positive
fibers, which were normalized (on spinal cord cross-
sections of the spinal cord) to the total number of la-
beled CST fibers cranial to the lesion center, showed that
the percentage of fibers present 5 mm distal to the le-
sion was reduced about 15-fold in rIL-1β-treated mice
compared with PBS-treated mice (Figure 6A) and was
increased about fivefold in IL-1βKO mice compared
with WT (Figure 6B). So far, these data provided strong
evidence for a neurodegenerative effect of rIL-1β applied
on the site of the lesion after spinal cord injury, while
genetic depletion of IL-1β resulted in a significantly
improved recovery after injury and had a strong benefi-
cial effect on plasticity (including local sprouting) of
CST fibers. GFAP immunoreactivity did not significantly
differ in mice with or without rIL-1β administration
(Figure 7A, C upper panels) and was also not signifi-
cantly different between WT and IL-1βKO mice when
analyzing the entire dorso-ventral axis of the spinal cord
(Figure 7B, 7C lower panels). In contrast, GFAP distribu-
tion was highly reduced (>60%) in IL-1βKO mice when
focusing the analysis on the white matter (Figure 7D), as
shown in a representative photomicrograph (Figure 7E)
demonstrating a substantially reduced astrogliosis after
SCI in the absence of systemic IL-1β.
The rostro-caudal lesion size (mean area on sagittal sec-
tions in the center of the lesion) and the lateral lesion
width (corresponding to the number of sagittal sections
that included the lesion, multiplied by the thickness of
each section) were determined by assessing the clearly
demarcated Iba1-positive area, but not the sparse Iba1
immunoreactivity present in the surrounding spared tissue
(Figure 8). Application of rIL-1β did not influence the size
of the lesion in the center of the spinal cord (Figure 8A),
but did result in a lesion almost 100 μm wider compared
with PBS-treated mice (from 500 μm in control mice to
600 μm in rIL-1β-treated mice; Figure 8B). On the con-
trary, systemic deficiency of IL-1β resulted in a signifi-
cantly smaller lesion (almost 40% smaller than in WT
mice; Figure 8C), as shown in a representative photo-
micrograph of the center of the lesion (Figure 8E lower
panels); this was also reflected in a reduced lesion width
(25% smaller in IL-1βKO mice; Figure 8D).
Discussion
In the present study we show for the first time that IL-
1β exerts detrimental effects on the plasticity of CNS
Figure 6 Quantification of biotinylated dextran amine-positive
corticospinal tract fibers in recombinant IL-1β-treated or
IL-1βKO mice. (A) The quantity of corticospinal tract (CST) fibers
(shown as a percentage of the total number of biotinylated dextran
amine (BDA)-positive fibers at C4 level in a standardized, 20 μm
wide area [18]) was significantly decreased 5 mm caudal to the
lesion in recombinant IL-1β (rIL-1β)-treated mice compared with
controls. (B) Conversely, the percentage of CST fibers of IL-1βKO
mice increased about fivefold compared with controls. Bars
represent the percentage of CST fibers at the lesion center (LC) and
in the area 0.5 mm, 2 mm and 5 mm distal to the LC. *P <0.05; n = 7
mice (PBS), n = 6 mice (rIL-1β), n = 9 mice (C57BL6/J), n = 6 mice
(IL-1βKO). Values throughout are represented as mean ± standard
error of the mean and P values were determined using the
Mann–Whitney U-test.
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axons after SCI. These data are in striking contrast to
our recent in vitro study, which revealed that IL-1β acts
as a potent inducer of axon outgrowth from organotypic
brain slices in vitro. IL-1β is one of the most extensively
studied proinflammatory cytokines; however, controver-
sial debate continues as to its function in the CNS. In
vivo, IL-1β may exert detrimental effects on damaged
nervous tissue [1], but some evidence exists for a benefi-
cial impact on myelination [15] and on peripheral nerve
regeneration following sciatic nerve injury [16,17]. After
SCI, IL-1β and its receptor are upregulated in rodents
and humans [13,30,31] in all resident cells of the CNS
(including neurons, but mainly astrocytes and microglia),
with a peak of mRNA expression 12 hours after lesion
[31]. A functional consequence of increased IL-1β ex-
pression may be apoptosis induction, suggested by a
threefold increase in caspase-3 activity that can be
reversed by administration of the IL-1 receptor antagon-
ist for 72 hours following lesion [32]. Direct application
of IL-1β has also been shown to affect the behavioral
outcome after glutamate-induced experimental spinal
cord injury [33]. Even if the precise mechanism of action
of IL-1β is still not perfectly clear, an extensive literature
describes the pathways that are influenced by this
Figure 7 Reduced glial fibrillary acidic protein expression in IL-1βKO white matter after spinal cord compression injury. (A),
(B) Quantification of the intensity of glial fibrillary acidic protein (GFAP) immunoreactivity in the entire dorso-ventral axis of the spinal cord from
600 μm cranial to 600 μm caudal to the lesion center (LC) in a standardized, 100 μm wide, area showed no significant difference in astrocytic
reactions between PBS-treated and recombinant IL-1β (rIL-1β)-treated animals (A) or between wildtype controls and IL-1βKO animals (B).
(C) Representative micrographs of spinal cord sections stained with GFAP showing the perilesional astroglia distribution for the four different
study conditions. Upper panels: comparison of PBS-treated and rIL-1β-treated spinal cord. Lower panels: comparison of wildtype control with
IL-1βKO spinal cord. (D) Quantification of GFAP intensity in a standardized area limited to the white matter (wm) shows a significant difference
of more than 60% in immunoreactivity and astroglia expression when using IL-1βKO mice compared with controls. (E) Higher magnification of
the boxes in (C) representing GFAP expression in the white matter of control and KO mice. *P <0.05; n = 5 mice (PBS), n = 5 mice (rIL-1β), n = 7
mice (C57BL6/J), n = 5 mice (IL-1βKO). Scale bar = 100 μm.
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cytokine. Of particular interest is the observation that
IL-1β injections stimulate macrophage activation and
myelin clearance in spinal cord white matter, while an
absence leads to an increased number of intact myelin
sheaths [34]. Furthermore, IL-1β application abrogates
neurotrophin-induced neuronal cell survival in vitro
[35,36]. Moreover, administration of IL-1β intrathecally
activates p38 mitogen-activated protein kinase, and leads
to high levels of inducible nitric oxide synthase and
release of nitric oxide [37]. However, none of these stud-
ies investigated the influence of IL-1β on CNS plasticity.
The present study demonstrates in vivo that the sum of
all these negative effects in the CNS appears to abrogate
potential IL-1-dependent axon elongation expected from
our recent in vitro study [5].
Here, we provide the first in vivo evidence for a sub-
stantial IL-1β effect on plasticity and lesion develop-
ment. We analyzed the effect of locally applied rIL-1β
and its constitutive deficiency on functional recovery,
CST fibers and astrogliosis in a mouse model of SCI,
which mimics the most common type of spinal cord in-
jury in humans [38]. Based on previous in vitro findings
demonstrating that a high therapeutic dosage of rIL-1β
increases axonal outgrowth in an organotypic slice cul-
ture model [5] we administered perilesionally a high
dose of rIL-1β after SCI (20 μg rIL-1β in Gelfoam). Un-
fortunately, this local application was lethal. However, a
lower, nonlethal dosage of rIL-1β (1 μg rIL-1β in Gel-
foam) led to a significantly impaired functional recovery
according to the BMS. We used a mild lesion to ensure
that any possible negative effect of the application of the
cytokine could be revealed. This treatment also resulted
in a highly reduced number of BDA-positive CST fibers
caudal to the lesion compared with PBS-treated mice.
Consistently, the analysis of the injured spinal cords of
IL-1β-deficient mice revealed a close to fivefold increase
in the number of CST fibers caudal to the lesion com-
pared with WT mice.
These mice also displayed a significantly improved
neurological outcome. Based on morphological criteria
[29], BDA-positive fibers counted caudal to the lesion
appeared to present newly formed fibers, but due to the
nature of the lesion we cannot exclude a small percentage
of (undetected) sparing. Counted fibers could thus be a
mixture of newly established fibers derived from the site
of the lesion and of those sprouting from uninjured fibers.
It is reasonable to assume that multiple spinal motor
systems are positively affected by the absence of IL-1β
(and the consecutively reduced astrogliosis as discussed
hereafter). The improvement in paw placement as an in-
dicator of CST function [27,28] and increased numbers
of anterogradely labeled CST nerve fibers in the IL-1β-
deficient injured spinal cord support the concept that
enhanced CST plasticity may significant contribute to the
improved clinical outcome demonstrated in our study.
Substantial differences between the in vivo and in vitro
model may explain why IL-1β stimulates neurite out-
growth in vitro [5] but has a negative impact on axon
plasticity in the present in vivo study. The in vitro study
was performed using organotypic slice cultures from
postnatal brains as previously described [22-25]. Acute
brain slices as used in our study, should be considered a
model for the early, highly acute phase of CNS trauma
since they are acutely excised from of the living brain;
most neurons are axotomized, the blood–brain barrier is
heavily damaged, high levels of neuronal death appear,
and astrocytes as well as many immune cells are acti-
vated [39,40]. Contrastingly, in the in vivo model used
here, the SCI is followed by at least three different in-
flammatory phases (acute, subacute and chronic) that
are characterized by dramatic differences, for example,
in terms of cytokine levels as well as immune cell activa-
tion and migration patterns [41]. The in vivo effects of
IL-1β on functional parameters become clearly detect-
able about 2 weeks after the highly acute phase. IL-1β
may therefore exert direct and/or indirect effects mainly
in the subacute or early chronic phase. In a landmark
paper, the Kapfhammer group demonstrated that neurite
outgrowth can only be reliably studied in embryonic and
postnatal brain slices until 4 days after birth [42]. Brain
slice experiments are therefore performed with embryonic
or early postnatal brains. In later developmental phases,
neurite outgrowth from slices is substantially reduced or
absent. A further difference between the models is the ab-
sence of systemic neuroendocrinological influences in the
brain slice model. The contradicting results in our brain
slice study in vitro [5] and the present in vivo study may
thus be due to differences in the CNS region (cortex
(See figure on previous page.)
Figure 8 Application of recombinant IL-1β and its deficiency influence lesion size after spinal cord compression injury. (A) to (D)
Quantification of the lesion size and lesion width based on a clearly distinguishable Iba1-positive area. Lesion size measurement in the central
sections of recombinant IL-1β (rIL-1β)-treated mice indicated no difference compared with controls (A), while the lesion width was about 20%
greater (B). Both the lesion size (C) and the lesion width (D) were reduced by 40% and 25%, respectively, in IL-1βKO mice compared with
controls. (E) Representative micrographs of Iba1 immunoreactive microglia distribution around the compression injury site in spinal cord sections.
Upper panels: comparison of PBS-treated and IL-1β-treated spinal cord. Lower panels: comparison of wildtype control with IL-1βKO spinal cord.
Dashed line, area of the lesion. Iba1 intensity did not differ significantly between groups (data not shown). *P <0.05; n = 5 mice (PBS), n = 5 mice
(rIL-1β), n = 7 mice (C57BL6/J), n = 5 mice (IL-1βKO). Scale bar = 100 μm.
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versus spinal cord), the inflammatory phase, the develop-
mental stage (postnatal versus adult) or the presence or
absence of systemic neuroendocrinological influences.
In the present study we also show significantly reduced
astrogliosis in the perilesional white matter in IL-1βKO
mice. This is in line with the role of IL-1β as an astroglial
growth factor in the mammalian brain (promoting prolif-
eration) [43] and with the IL-1β-dependent astrocyte acti-
vation following CNS injury, demonstrated in a murine
corticectomy model [44], leading to exacerbated astroglio-
sis. However, in contrast to these studies, which describe
early stages after brain injury, we here demonstrate that
reduced astrogliosis in the absence of IL-1β is still present
2 weeks after injury. Consistently, we also find a greatly
reduced lesion size (and consequently more spared spinal
cord tissue).
While the results of the present study are encouraging
to further investigate IL-1β modulation for spinal cord
repair, they should be interpreted with care keeping in
mind the complexity of the plethora of potential mechan-
isms as outlined in the introduction. Further studies
are needed to elucidate the intricate network of IL-1β
mechanisms of action after SCI, which is likely to be
multifaceted and not limited to demyelination, cell death
and cytotoxic neuroinflammation.
Conclusion
Our results show that IL-1β has a strong negative effect
on axon plasticity, lesion development and gliosis after
SCI, associated with substantially impaired functional out-
come. In particular, mice with constitutive absence of IL-
1β revealed a close-to-opposite effect compared with mice
treated with rIL-1β, since IL-1βKO mice were character-
ized by a smaller lesion size, less astrogliosis and a greater
number of labeled CST fibers caudal to the lesion, which
resulted in a significantly improved neurological outcome.
These data provide a strong basis for further studies to be
conducted with the goal of developing therapeutic strat-
egies targeting the IL-1β pathways in spinal cord recovery
after injury.
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